Veyonda (idronoxil)

P1, N=10, Terminated, Noxopharm Limited | Trial completion date: Aug 2023 --> May 2023 | Active, not recruiting --> Terminated; Slow recruitment

P1b/2a, N=21, Terminated, Noxopharm Limited | Active, not recruiting --> Terminated; Slow Recruitment

P1, N=10, Active, not recruiting, Noxopharm Limited | N=34 --> 10 | Trial primary completion date: Jul 2023 --> May 2023

P1, N=34, Active, not recruiting, Noxopharm Limited | Recruiting --> Active, not recruiting | Trial completion date: Jun 2024 --> Aug 2023 | Trial primary completion date: Jun 2024 --> Jul 2023

P1b/2a, N=21, Active, not recruiting, Noxopharm Limited | Recruiting --> Active, not recruiting | N=70 --> 21 | Trial completion date: Feb 2024 --> Aug 2023

Tumor-intrinsic ENOX2 expression is associated with tumor phenotype and PFS in NPC. Targeting ENOX2 with IDX and cisplatin impose qualitative control of T-cell response by preferentially increasing immune cells infiltration, Tem differentiation and tumor suppression. We suggest that ENOX2 inhibition may be a promising therapeutic strategy to enhance the effects of chemotherapy.

P1b/2a, N=70, Recruiting, Noxopharm Limited | N=100 --> 70 | Trial primary completion date: Oct 2022 --> Aug 2023

P1, N=34, Recruiting, Noxopharm Limited | Not yet recruiting --> Recruiting

P1, N=34, Not yet recruiting, Noxopharm Limited

P1b/2a, N=100, Recruiting, Noxopharm Limited | Not yet recruiting --> Recruiting

All men had received prior treatment with ASI and docetaxel, and 95% (53/56) had received cabazitaxel. NOX66 with Lu-PSMA-617 is a safe and feasible therapeutic strategy in men treated 3rd line and beyond for mCRPC. PSMA SUVmean, PSMA avid tumour volume and duration of treatment with ASI were independently associated with outcome.

NOX66 with LuPSMA-617 is a safe and feasible therapeutic strategy in men treated with third-line therapy and beyond for mCRPC.